BioCentury | Feb 17, 2014
Company News

DanDrit Biotech USA, Oxford BioMedica, myTomorrows cancer news

...later this year and declined to disclose financial terms. Oxford BioMedica is developing preventive vaccine TroVax...
BioCentury | Apr 29, 2013
Strategy

Zerhouni's progress report

...Ultra-low molecular weight heparin Prevent venous Thromboemoblism (VTE) Ph III Withdrew regulatory apps in 2012 TroVax...
BioCentury | Mar 11, 2013
Clinical News

TroVax: Phase II started

...said the Velindre Cancer Centre began the open-label, U.K. Phase II SKOPOS trial to evaluate TroVax...
...JHMRF) and the Velindre Cancer Centre Stepping Stones Appeal, while Oxford BioMedica will provide TroVax. TroVax...
...and Co. (NYSE:LLY, Indianapolis, Ind.) markets Alimta pemetrexed. Oxford BioMedica plc (LSE:OXB), Oxford, U.K. Product: TroVax...
BioCentury | Jan 7, 2013
Finance

4Q Stock Wrap-Up: Go big or go home

...following arthroscopic partial meniscectomy surgery Oxford BioMedica plc (LSE:OXB) Discontinues a Phase II trial of TroVax...
BioCentury | Oct 15, 2012
Finance

Highlights of weekly biotech stock moves

...LSE:OXB) lost 0.23p to 2.51p last week after stopping a U.S. Phase II trial of TroVax...
BioCentury | Oct 15, 2012
Clinical News

TroVax: Phase II discontinued

...Oxford stopped an open-label, U.S. Phase II trial comparing TroVax plus docetaxel vs. docetaxel alone in...
...Preliminary data showed a trend towards increased time to disease progression in patients who received TroVax...
...Cancer Vaccines meeting in Brussels in December. Oxford said investigator-led, U.K. Phase II trials of TroVax...
BioCentury | Oct 11, 2012
Company News

Oxford discontinues U.S. TroVax prostate cancer trial

...Oxford BioMedica plc (LSE:OXB) stopped a U.S. Phase II trial of TroVax in patients with metastatic...
...Preliminary data showed a trend towards increased time to disease progression in patients who received TroVax...
...was off 0.18p to 2.58p on Wednesday. Oxford said investigator-led, U.K. Phase II trials of TroVax...
BioCentury | Jul 16, 2012
Clinical News

TroVax: Phase II started

...at Cardiff University (Cardiff, U.K.) began the open-label, U.K. Phase II TaCTiCC trial to evaluate TroVax...
...from Cardiff University and Cancer Research Wales (Cardiff, U.K.), while Oxford BioMedica will provide TroVax. TroVax...
...II testing to treat hormone-refractory prostate cancer (HRPC). Oxford BioMedica plc (LSE:OXB), Oxford, U.K. Product: TroVax...
BioCentury | May 19, 2011
Distillery Therapeutics

Indication: Cancer

...Phase III testing for renal cancer and Phase I testing for NSCLC and pancreatic cancer. TroVax...
BioCentury | Aug 2, 2010
Clinical News

TroVax: Phase II start

...will begin an open-label, U.S. Phase II trial to evaluate Taxotere docetaxel with or without TroVax...
...marketed by sanofi-aventis Group (Euronext:SAN; NYSE:SNY, Paris, France). Oxford BioMedica plc (LSE:OXB), Oxford, U.K. Product: TroVax...
Items per page:
1 - 10 of 102